Gold prices steady with focus on Ukraine-Russia, Jackson Hole
Investing.com - H.C. Wainwright assumed coverage on Assembly Biosciences (NASDAQ:ASMB) with a Buy rating and a $50.00 price target on Monday. The stock, currently trading at $25.44, has shown remarkable momentum with a 104% gain over the past six months, according to InvestingPro data.
The research firm cited the potential of Assembly’s clinical-stage antiviral pipeline to deliver significant value through its collaboration with Gilead Sciences (NASDAQ:GILD). The pipeline features oral therapies for hepatitis D virus (HDV) and herpes simplex virus (HSV). With a market capitalization of $396 million and impressive revenue growth of 55% in the last twelve months, Assembly is attracting increased investor attention.
H.C. Wainwright highlighted two lead programs: ABI-6250, an oral HDV entry inhibitor for chronic HDV infection, and ABI-5366, an oral long-acting helicase-primase inhibitor for recurrent genital HSV infection. Both programs are advancing through Phase 1 trials with encouraging third-quarter 2025 interim data.
The firm models a 95% probability that Gilead will opt in to ABI-6250 and a 50% probability for ABI-5366, with decisions expected after Phase 2 trials. These opt-ins could provide substantial non-dilutive capital and position Assembly to elect its 40% U.S. profit-share structure.
H.C. Wainwright believes Assembly is well-positioned to generate significant upside from two high-value infectious disease franchises, with its $50 price target implying meaningful upside from current levels. InvestingPro analysis reveals a Strong Buy consensus among analysts, with price targets ranging from $29 to $35. Subscribers can access 12 additional ProTips and comprehensive financial metrics for deeper analysis.
In other recent news, Assembly Biosciences, Inc. announced the pricing of a $130 million underwritten offering to support its viral disease therapeutic development programs. This offering involves approximately 6.6 million shares and warrants, priced at $19.60 per share of common stock, including pre-funded warrants and Class A and Class B warrants. Additionally, Assembly Bio reported positive interim results from a Phase 1b study of its HSV treatment, ABI-5366, which showed a 94% reduction in HSV-2 shedding rate and genital lesions in patients. The results exceeded the company’s target, indicating significant potential for the treatment of recurrent genital herpes.
The company also revealed positive topline results from a Phase 1b study of ABI-4334, a treatment for chronic hepatitis B virus infection, with notable reductions in HBV DNA and RNA levels. Assembly Biosciences has expanded its stock plans and appointed a new Chief Financial Officer, following approvals from its Annual Meeting of Stockholders. Amendments to the 2018 Stock Incentive Plan and the Employee Stock Purchase Plan were approved, increasing the number of shares reserved for issuance. These developments highlight Assembly Bio’s continued efforts in advancing its research programs and organizational structure.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.